Figure 3.

CCL19 and CCL21 and 60-day mortality in patients hospitalized with COVID-19 (n = 414). A, Kaplan-Meier analysis 60-day mortality (n = 37) according to tertiles (T) of CCL19 (T1 ≤ 1.27 ng/mL, T2 1.28–2.09 ng/mL, T3 > 2.10 ng/mL) and CCL21 (T1 ≤ 1.41 ng/mL, T2 1.42–2.44 ng/mL, T3 > 2.45 ng/mL). B, Temporal profile of CCL19 and CCL21 during the first 10 days after inclusion according to 60-day mortality. Data in B is shown as estimated marginal means and 95% CI. The P values reflect the group (outcome) effect from the linear mixed models with subject as random effect, and time and mortality as fixed effects (also as interaction) in addition to age, sex, estimated glomerular filtration rate, and treatment modalities. Shaded areas show reference value range from healthy controls. * P < .05, ** P < .01, *** P < .001 between groups. Abbreviation: BL, baseline.